A recent study indicates that patients who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise programs.
Findings released in a leading medical journal points out that while overweight individuals can lose a large proportion of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"People buying these drugs should be cognizant of the danger of fast rebound weight gain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of regain means a return to starting weight within about one and a half years.
Analyzing Therapies
The research, which reviewed 37 of trials involving thousands of participants, compared the results of GLP-1 agonists with other pills.
Scientists point out that people who lose weight through diet and exercise usually experience a more gradual creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Doctors believe the way of the drugs is key to understanding the accelerated regain.
The injections imitate a natural hormone called GLP-1, which moderates appetite.
"Long-term administration of GLP-1 levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication leads to hunger is uncontrolled, making overeating much more probable."
An Ongoing Condition?
The NHS advise the jabs for people with weight-linked medical conditions, alongside recommended lifestyle changes.
Many experts say that, given the significant potential of weight regain, the therapy should be considered life-long.
This perspective is echoed by pharmaceutical companies, who note that the results "highlight the long-term character of excess weight," similar to managing conditions like diabetes.
Patient Testimonies
Users who have discontinued the medication explain a powerful return of cravings.
"It was like a trigger flipping and I was suddenly starving," said one woman.
This difficulty is exacerbated if individuals have not developed lasting dietary or behavioural changes during treatment.
Significant Interest
Survey data indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with demand continuing to grow.
- Adoption is greater among women compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Finally, experts emphasize that while the jabs are effective agents for weight loss, they are not a standalone cure and long-term success likely depends on combined behavioural support.
